Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125654291 | 12565429 | 1 | I | 20160706 | 20160718 | 20160718 | EXP | DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-058901 | BRISTOL MYERS SQUIBB | 59.00 | YR | M | Y | 0.00000 | 20160718 | CN | GB | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125654291 | 12565429 | 1 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 90 MG/M2, QCYCLE | U | 0 | 90 | MG/M**2 | |||||||
| 125654291 | 12565429 | 2 | PS | ETOPOSIDE PHOSPHATE | ETOPOSIDE PHOSPHATE | 1 | Unknown | 270 MG/M2, QCYCLE | U | 20457 | 270 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125654291 | 12565429 | 1 | Nasal sinus cancer |
| 125654291 | 12565429 | 2 | Nasal sinus cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125654291 | 12565429 | OT |
| 125654291 | 12565429 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125654291 | 12565429 | Cytomegalovirus viraemia | |
| 125654291 | 12565429 | Product use issue | |
| 125654291 | 12565429 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |